| Similar Articles |
|---|
 |
Chemistry World
September 26, 2012
Andrew Turley |
Boehringer drops virology R&D German pharma company Boehringer Ingelheim is to close its R&D site in Laval, Canada, in early 2013, with the loss of 170 jobs.   |
The Motley Fool
January 15, 2009
Robert Steyer |
Medicis Tries to Save Face The wrinkle-removal drugmaker hopes it can smooth out a tough economy. |
The Motley Fool
March 19, 2009
Brian Orelli |
Teva: An Equal-Opportunity Bully Making money by picking on the little guy, too. |
The Motley Fool
February 28, 2011
Cindy Johnson |
Medicis Pharmaceutical Shares Popped: What You Need to Know Medicis Pharmaceutical Corporation popped 26% in intraday trading today after reporting an inline quarter and announcing a licensing agreement with Teva Pharmaceutical Industries. |
Chemistry World
July 30, 2013
Emma Stoye |
Thousands face job cuts after Valeant's Bausch buyout Canadian pharmaceutical company Valeant plans to lay off up to 2700 staff to help finance its $8.7 billion acquisition of US eye health specialist Bausch & Lomb. |
The Motley Fool
March 12, 2009
Robert Steyer |
A Valeant Effort During this decade, Valeant has had four CEOs, two names, and multiple strategies. And now the constantly changing drugmaker is trying another. |
The Motley Fool
January 2, 2004
Dave Marino-Nachison |
Medicis: Skin Is In The drug maker has a strong balance sheet and a commitment to product development. |
The Motley Fool
July 28, 2011 |
Medicis Pharmaceutical Earnings Preview Medicis Pharmaceutical will unveil its latest earnings on Tuesday, August 2. |
Chemistry World
February 23, 2015
Phillip Broadwith |
Valeant to buy Salix for $14.5bn Serial acquirer Valeant has agreed to buy gastroenterology specialist Salix Pharmaceuticals for $14.5 billion |
The Motley Fool
August 31, 2007
Rich Smith |
A Healthy Buyback for Medicis? Investors, can Medicis pay its own way? And even if it can, should it? |
The Motley Fool
March 30, 2011
Brian Orelli |
Valeant Vultures Will Cephalon manage to rebuff Valeant's advances? |
The Motley Fool
May 6, 2009
Robert Steyer |
Getting Ahead by Getting Rid of Wrinkles Medicis gets the FDA OK for an anti-wrinkle product as the market for Botox and other cosmetic skin drugs sags. |
The Motley Fool
September 25, 2008
Brian Orelli |
Medicis Restates, Investors Panic Medicis says it'll have to restate earnings. |
Chemistry World
July 28, 2014
Andy Extance |
Takeover battle pushes Allergan to cut R&D jobs Despite a quarterly sales increase it describes as its strongest ever, Botox maker Allergan is laying off 1500 staff as it seeks to fend off a hostile takeover. |
The Motley Fool
March 21, 2005
Rich Duprey |
Inamed Buoyant on Medicis Buyout Breast-implant maker Inamed will be acquired in a $2.8 billion deal with skin-care pharmaceutical Medicis. Inamed investors should now decide whether they want to be a part of Medicis or enjoy the profits realized from the offer. |
Pharmaceutical Executive
November 1, 2005
Sara Calabro |
Valeant Pharmaceuticals is Soldiering On Valeant Pharmaceuticals' new CEO Tim Tyson restructures the company after legal and financial troubles. |
The Motley Fool
December 16, 2005
Stephen D. Simpson |
A Romantic Rectangle in Health Care First Medicis wants Inamed, then Allergan wants Inamed. Now Mentor wants Medicis. Strange days in health care, to be sure. Investors, take note. |
The Motley Fool
April 11, 2011
Jim Mueller |
A Missed Opportunity Cephalon showed up on my screen as a potential buy, but others liked it, too. |
Chemistry World
April 29, 2014
Phillip Broadwith |
Valeant launches hostile bid for Allergan US drugmaker Valeant has lined up its next takeover target: Botox provider Allergan. Valeant has taken its proposal direct to shareholders, but Allergan has activated a 'poison pill' defense to buy time. |
The Motley Fool
December 15, 2003
Alyce Lomax |
No Wrinkles for Medicis Medicis Pharmaceuticals announced that the FDA has approved its injectable wrinkle-filling gel, Restylane. Allergan's Botox has found a new competitor in the fountain-of-youth market. |
